Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APL-501 in advanced solid tumors
NCT03053466Phase 1Completed
- Sponsor
- Apollomics, Inc.
- Start
- Mar 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of geptanolimab in solid tumor and carcinoma of unknown primary (CUP), sponsored by Apollomics, Inc. Primary endpoint: Number of participants with treatment related adverse events. Started Mar 2017; status: completed.
02
Drugs
geptanolimab
03
Conditions
solid tumorcarcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT03053466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053466.